No quarterly revenue total was found in Savara Inc's SEC filings.
Savara Inc (SVRA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$30.0 million. As of Jun 30, 2026 it held $173.0 million in cash and investments and $31.2 million in total debt.
Revenue
—
Net income
$-40.23M
-32.3% vs year-ago quarter
Operating cash flow
$-29.75M
-13.3% vs year-ago quarter
Free cash flow
$-29.97M
-14.1% vs year-ago quarter
EPS
$-0.16
-14.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
205.46M
+18.9% vs year-ago quarter
Net cash
$141.83M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SVRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1160308
- Former names
- Mast Therapeutics, Inc. (until Apr 25, 2017); ADVENTRX PHARMACEUTICALS INC (until Mar 1, 2013); BIOKEYS PHARMACEUTICALS INC (until May 15, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$41.0M | -$39.0M | -$33.4M | -$30.3M | -$31.4M |
| Net income | -$40.2M | -$37.3M | -$32.2M | -$29.6M | -$30.4M |
| Diluted EPS | -$0.16 | -$0.15 | -$0.13 | -$0.14 | -$0.14 |
| Operating cash flow | -$29.7M | -$33.0M | -$25.1M | -$22.5M | -$26.3M |
| Free cash flow | -$30.0M | -$33.1M | -$25.1M | -$22.5M | -$26.3M |
| Total assets | $192.1M | $221.6M | $253.4M | $140.9M | $163.8M |
| Total liabilities | $48.5M | $45.6M | $50.3M | $46.5M | $43.3M |
| Stockholders' equity | $143.7M | $176.0M | $203.1M | $94.4M | $120.5M |
| Cash and investments | $173.0M | $202.8M | $235.7M | $124.4M | $146.4M |
| Total debt | $31.2M | $30.1M | $30.0M | $29.8M | $29.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Jun 8, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | Apr 24, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement
|
Mar 13, 2026 | Mar 10, 2026 |
| 10-K | Annual report | Mar 13, 2026 | Dec 31, 2025 |
All 1000 Savara Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.